series-b
Stage
1
Investors
About
Starna Therapeutics develops liver-extrinsic targeted lipid nanoparticle (LNP) delivery systems to enable RNA-based therapeutics such as in vivo cell therapies and vaccines, focusing on tissue- and cell-specific delivery beyond the liver.
Explore Starna Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.